Can less be more? new study tests lower drug dose to keep leukemia at bay
NCT ID NCT07163793
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a lower dose of the drug venetoclax can be safely given to adults with acute myeloid leukemia (AML) who are already in remission. The goal is to reduce severe side effects like low white blood cell counts while still preventing the cancer from coming back. About 41 participants will take a reduced dose for several cycles, and researchers will monitor how well they tolerate it and how long they stay cancer-free.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA IN REMISSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zuckerberg Cancer Center
RECRUITINGNew Hyde Park, New York, 11042, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Selective immune cell removal may tame transplant complications
- New stem cell transplant method aims to cut complications in young blood cancer patients
- New vaccine aims to shield transplant patients from deadly virus
- New transplant method aims to reduce dangerous immune reactions
- New hope for older leukemia patients: drug may keep cancer away after transplant
- New drug aims to keep leukemia away after transplant